SlateStone Wealth’s Surgery Partners SGRY Stock Holding History

SlateStone Wealth’s Portfolio SGRY Stock Details SGRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,000	Closed	-$235K	–	212
2019 Q4	$235K	Buy	+15,000	New	+$170K	0.05%	193

Other funds holding SGRY

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

KSCM

King Street Capital Management New York $328M AUM 0.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Centerbridge Partners New York $61.1M AUM 3.67% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SlateStone Wealth's SGRY Position: Q1 2020 in Review

SlateStone Wealth sold out of Surgery Partners (SGRY) in Q1 2020, closing a stake of 15,000 shares — an estimated $235K sold.

SlateStone Wealth first reported a position in SGRY in Q4 2019 and held it in 1 quarter. The position peaked at $235K in Q4 2019. 87 funds tracked by Wall St. Rank hold SGRY as of Q1 2020.

SlateStone Wealth reported no remaining Surgery Partners position as of Q1 2020 after selling out during the quarter.
SlateStone Wealth sold 15,000 Surgery Partners shares in Q1 2020, an estimated $235K.
SlateStone Wealth first reported a position in Surgery Partners in Q4 2019 and held it in 1 quarter.
SlateStone Wealth's Surgery Partners position peaked at $235K in Q4 2019.
87 funds tracked by Wall St. Rank held Surgery Partners as of Q1 2020.

Based on SlateStone Wealth's 13F filing for Q1 2020, filed 28 Apr 2020.